BFG
XBIT icon

Beacon Financial Group’s XBiotech XBIT Stock Holding History

Beacon Financial Group’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,000
Closed -$321K – 173
2015
Q3 		$321K Hold
20,000
– – 0.08% 139
2015
Q2 		$365K Buy
+20,000
New +$415K 0.08% 134

Other funds holding XBIT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NFA
Nationwide Fund Advisors Columbus, Ohio $2.28B AUM 12.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $1.48B AUM 26.15% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return

Beacon Financial Group's XBIT Position: Q4 2015 in Review

Beacon Financial Group sold out of XBiotech (XBIT) in Q4 2015, closing a stake of 20,000 shares — an estimated $321K sold.

Beacon Financial Group first reported a position in XBIT in Q2 2015 and held it in 2 quarters. The position peaked at $365K in Q2 2015. 38 funds tracked by Wall St. Rank hold XBIT as of Q4 2015.

  • Beacon Financial Group reported no remaining XBiotech position as of Q4 2015 after selling out during the quarter.
  • Beacon Financial Group sold 20,000 XBiotech shares in Q4 2015, an estimated $321K.
  • Beacon Financial Group first reported a position in XBiotech in Q2 2015 and held it in 2 quarters.
  • Beacon Financial Group's XBiotech position peaked at $365K in Q2 2015.
  • 38 funds tracked by Wall St. Rank held XBiotech as of Q4 2015.

Based on Beacon Financial Group's 13F filing for Q4 2015, filed 4 Jan 2016.